The 7+3 regimen is a chemotherapy regimen used as first line induction therapy to bring about remission in acute myeloid leukemia, excluding the acute promyelocytic form of the disease, which is treated differently. It combines seven days of continuous intravenous cytarabine with three concurrent days of an anthracycline, most often daunorubicin, though idarubicin, doxorubicin, or mitoxantrone can be substituted. Developed in 1973, the combination has remained the backbone of standard induction therapy for acute myeloid leukemia for close to five decades, with roughly 35 to 40 percent of younger adult patients becoming long term survivors after starting treatment with it.
Facts
Connections
Treats
Source 7+3 (chemotherapy) (Wikipedia)
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
7+3 (chemotherapy) (Wikipedia)
Lead section
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always the case).
Treats: Acute Myeloid Leukemia, Lead section (treats 319775)
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always the case).
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.